Xeris reported 34% growth in product sales, with Recorlev up 81%, and raised its 2026 sales forecast. Gvoke only improved from the prior quarter and Keveyis stayed steady, but overall sales growth and lower interest costs support a stronger outlook.
The sales gains and higher company forecast point to stronger demand. Paying off its debt also removes nearly $3 million in yearly interest costs. Recorlev drove much of the growth. Gvoke improved only from the prior quarter, and Keveyis stayed steady.
Follow Xeris Biopharma Holdings (XERS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for XERS